Want to see BEAM full AI Analyst Report?
BEAM Stock Chart & Stats
$31.39
-$0.69(-2.55%)
At close: 4:00 PM EST
$31.39
-$0.69(-2.55%)
Day’s Range― - ―
52-Week Range$15.60 - $38.26
Previous CloseN/A
Volume491.48K
Average Volume (3M)2.44M
Market Cap
$2.71B
Enterprise Value$1.50K
Total Cash (Recent Filing)$1.21B
Total Debt (Recent Filing)$250.82M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Aug 11, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding102,879,210
10 Day Avg. Volume2,799,131
30 Day Avg. Volume2,443,075
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.21
Price to Sales (P/S)19.62
P/FCF Ratio-7.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$52.91Price Target Upside68.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.37
Revenue Forecast (FY)$82.09M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthBeam’s low reported leverage and sizable equity provide durable financial flexibility for an R&D-intensive biotech. A stronger balance sheet reduces near-term refinancing pressure, supports continued drug development spending, and lessens forced dilution risk while programs advance.
Sustained Revenue GrowthRecovering and growing TTM revenue signals increasing traction for Beam’s platform and collaborations. Durable top-line momentum can expand non-dilutive funding via partnerships and milestones, improving runway and validating commercial interest in the base-editing approach.
Governance ContinuityBroad shareholder support for the board, management and auditor reduces governance risk and preserves strategic continuity. Stable oversight matters for multi-year R&D plans, helping execute collaborations and capital strategies without disruptive leadership changes.
Bears Say
Heavy Cash BurnLarge negative operating and free cash flow is a structural constraint for a pre-revenue biotech: it necessitates ongoing external financing, increases dilution risk, and limits optionality on program prioritization unless sustained revenue or funding ramps materially.
Persistent UnprofitabilityA deeply negative net margin reflects that R&D and operating costs far exceed revenue today. If losses persist, they can erode equity over time and force trade-offs between investing in pipeline programs and preserving capital, impacting long-term value creation.
Adverse Arbitration OutcomeThe arbitration ruling removes a potential claim and monetary recovery for Beam while affirming Prime’s development rights. This structurally reduces potential licensing income and narrows exclusive rights from that collaboration, weakening expected future revenue streams.
Beam Therapeutics News
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $15.60 and its highest was $38.26 in the past 12 months.
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $2.71B.
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 20 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on May 07, 2026. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$1.028 by $0.118.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics pays a Quarterly dividend of $0.225 which represents an annual dividend yield of N/A. See more information on Beam Therapeutics dividends here
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -1.11.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 102,879,210 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$0.91 in its last earnings report, beating expectations of -$1.028. Following the earnings report the stock price went down -2.69%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Currently, no hedge funds are holding shares in BEAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beam Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.91 (68.55% Upside)
$52.91 (68.55% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.95%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
BEAM Stock 12 Month Forecast
Average Price Target
$52.91
▲(68.55% Upside)
Technical Analysis
Denali Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Immunocore Holdings
―
Ownership Overview
3.39% Insiders
21.84% Mutual Funds
0.09% Other Institutional Investors
45.45% Public Companies and Individual Investors